Coltac Therapeutics
Israel
unknown
unknown
Stage
About
Coltac Therapeutics develops molecular-glue therapeutics by using a proprietary high-throughput E. coli-based positive-selection screening system. The company combines structural biology and computational approaches to select E3 ligase libraries and identify compounds that enhance E3–target binding for targeted protein degradation in cancer.
Explore Coltac Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.